| Wiskott-Aldrich Syndrome
Cutaquig vs Privigen
Side-by-side clinical, coverage, and cost comparison for wiskott-aldrich syndrome.Deep comparison between: Cutaquig vs Privigen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrivigen has a higher rate of injection site reactions vs Cutaquig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Privigen but not Cutaquig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cutaquig
Privigen
At A Glance
SC injection
Weekly
Immune globulin (IGSC)
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Primary immune deficiency disorder
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Primary immune deficiency disorder, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC dose based on pharmacokinetic and clinical response; for patients switching from IGIV, calculate initial weekly dose by dividing monthly IGIV dose by weeks between infusions and multiplying by adjustment factor of 1.30; for patients switching from IGSC, maintain same weekly dose; dosing interval from daily up to every other week.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 200-800 mg/kg IV every 3-4 weeks.
Immune thrombocytopenic purpura 1 g/kg IV daily for 2 consecutive days (total dose 2 g/kg).
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Loading dose: 2 g/kg IV in divided doses over 2-5 consecutive days; maintenance dose: 1 g/kg IV every 3 weeks.
Contraindications
- Previous anaphylactic or severe systemic reaction to subcutaneous administration of human immune globulin or to any component of CUTAQUIG, including Polysorbate 80
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human globulin treatment
- History of anaphylactic or severe systemic reaction to human immune globulin
- Hyperprolinemia (product contains L-proline stabilizer)
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=5%) Local infusion site reactions (redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, cough
Postmarketing Pancytopenia, leukopenia, hemolytic anemia, anaphylactic reaction, hypersensitivity reaction, angioneurotic edema, thromboembolism, Stevens-Johnson syndrome, aseptic meningitis, seizures, cardiac arrest, respiratory failure, pulmonary embolism, acute renal failure, dizziness, nausea, pruritus, fatigue
Most common (>5%) Headache, fatigue, nausea, chills, vomiting, back pain, elevated body temperature, diarrhea, cough, stomach discomfort, asthenia, hypertension, pain in extremity, hemolysis, anemia, leukopenia, rash
Serious Hypersensitivity, aseptic meningitis syndrome, hemolysis, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, hyponatremia, volume overload, transfusion-related acute lung injury
Postmarketing Decreased neutrophil count, hemoglobinuria, renal failure, photophobia, cerebral edema, pruritus, cardiac arrest, thromboembolism, Stevens-Johnson syndrome, ARDS, seizures, hepatic dysfunction
Pharmacology
Immune globulin replacement; CUTAQUIG supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, with IgG subclass distribution closely proportional to native human plasma, restoring abnormally low IgG levels to the normal range to help prevent infections in primary humoral immunodeficiency.
PRIVIGEN is an intravenous immunoglobulin that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; the mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cutaquig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
Privigen
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Cutaquig
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Privigen
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Cutaquig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Privigen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Octapharma IgCares Co-Pay Assistance Program: CutaquigCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Privigen.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CutaquigView full Cutaquig profile
PrivigenView full Privigen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.